Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
Related Experiment Video
Updated: Oct 28, 2025
05:49
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses
Published on: November 21, 2023
2.0K
Jake A Ruddy1, Brian J Boyarsky1, Justin R Bailey2
1Department of Surgery.
AIDS (London, England)
|July 14, 2021
Abstract:
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.
